Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REL-1017 as Adjunctive Treatment for Major Depressive Disorder
NCT06735079Phase 3Withdrawn
- Sponsor
- MGGM LLC
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing REL-1017 with Placebo (2 arms). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 28 days. Planned start Dec 2024; status: withdrawn.
02
Drugs
esmethadone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06735079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06735079.